Insight Genetics Licenses ALK Gene Mutations from St. Jude for Dx Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Insight Genetics today announced an exclusive worldwide licensing agreement with St. Jude Children's Hospital to develop a diagnostic test directed at the anaplastic lymphoma kinase, or ALK, gene to better monitor cancer patients and enable physicians to prescribe more effective treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.